Kaliphos (Dipotassium Phosphate, Potassium Dihydrogen Phosphate)

Dipotassium phosphate dissociates after IV administration, releasing phosphate ions that participate in ATP production, cellular signalling, and acid‑base buffering, while also providing potassium to help maintain normal membrane potentials and renal electrolyte handling.

The dose of Kaliphos is determined by the prescribing clinician based on the patient’s serum phosphate and potassium levels, clinical condition, and renal function. The healthcare professional sets the appropriate volume and infusion rate.

Safety data for Kaliphos in pregnancy and lactation are limited. It should be used only if the expected benefit to the mother outweighs any potential risk to the fetus or infant, and the decision must be made by the treating physician.

To order Kaliphos, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Kaliphos provides both dipotassium phosphate and potassium dihydrogen phosphate in a single IV formulation, offering simultaneous phosphate and potassium repletion. Compared with sodium‑based phosphate solutions, Kaliphos avoids additional sodium load, which can be advantageous in patients requiring fluid restriction.

Kaliphos should be stored at 2‑8 °C, protected from light, and kept in its original container. Do not freeze or shake the solution, and discard any product that appears cloudy or discoloured.

Kaliphos is administered intravenously by a qualified healthcare professional. The solution is typically infused through a peripheral or central line at a rate prescribed by the clinician, with continuous monitoring of vital signs and electrolyte levels.

Serious risks include severe hyperphosphatemia leading to calcium‑phosphate precipitation, life‑threatening cardiac arrhythmias from rapid electrolyte shifts, anaphylactic reactions, metabolic acidosis, and acute renal failure. Prompt recognition and management are essential.

Kaliphos is contraindicated in patients with known hypersensitivity to its components, uncontrolled hyperphosphatemia or hyperkalemia, and those with severe renal failure where phosphate accumulation cannot be safely managed. Clinicians should assess each patient individually.